GSK

GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status
BioSpace
GSK
Pfizer
RSV
vaccines
Arexvy
Flag link:
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
Reuters
GSK
RSV
vaccines
Emma Walmsley
Pharma CEOs
Flag link:
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset
Fierce Biotech
Merck
GSK
chronic cough
Bellus Health
gefapixant
Camlipixant
Flag link:
GSK cancer drug Blenrep gets surprise trial win
GSK cancer drug Blenrep gets surprise trial win
BioPharma Dive
GSK
Blenrep
clinical trials
Multiple Myeloma
Flag link:
GSK says new inhaler will help slash its carbon footprint
GSK says new inhaler will help slash its carbon footprint
Pharmaphorum
GSK
inhalers
carbon emisssions
sustainability
Flag link:
Hepatitis B drug developers chart slow progress forward, just like hep C before it
Hepatitis B drug developers chart slow progress forward, just like hep C before it
Fierce Biotech
hepatitis B
hepatitis C
drug development
Assembly Biosciences
GSK
Aligos Therapeutics
Flag link:
GSK outpaces Pfizer in RSV vaccine market
GSK outpaces Pfizer in RSV vaccine market
BioPharma Dive
GSK
Pfizer
vaccines
RSV
Arexvy
Abrysvo
Flag link:
GSK Touts Strong Q3 Performance on the Back of Arexvy, Shingrix Sales
GSK Touts Strong Q3 Performance on the Back of Arexvy, Shingrix Sales
BioSpace
GSK
earnings
Arexvy
Shingrix
Flag link:
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
GSK
JNJ
hepatitis B
JNJ-3989
Janssen
Flag link:
GSK's Jemperli prolongs life in endometrial cancer trial. Will FDA label expansion come next?
GSK's Jemperli prolongs life in endometrial cancer trial. Will FDA label expansion come next?
Fierce Pharma
GSK
Jemperli
endometrial cancer
clinical trials
Flag link:
GSK targets younger age group with RSV vaccine Arexvy
GSK targets younger age group with RSV vaccine Arexvy
Pharmaphorum
GSK
RSV
Arexvy
vaccines
Flag link:
Pfizer beats out GSK with FDA nod for first 5-in-1 meningitis shot
Pfizer beats out GSK with FDA nod for first 5-in-1 meningitis shot
Fierce Pharma
Pfizer
GSK
vaccines
FDA
Penbraya
meningococcal disease
Flag link:
In 2nd big ADC deal of the day, GSK inks $2B-plus pact for Hansoh gynecology cancer asset
In 2nd big ADC deal of the day, GSK inks $2B-plus pact for Hansoh gynecology cancer asset
Fierce Biotech
GSK
antibody-drug conjugate
Hansoh Pharmaceutical
Flag link:
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
Fierce Pharma
Merck
GSK
Keytruda
Jemperli
ESMO
nonsquamous non-small cell lung cancer
Flag link:
GSK Settles Zantac Cases After Claims Popular Heartburn Drug Causes Cancer
GSK Settles Zantac Cases After Claims Popular Heartburn Drug Causes Cancer
Forbes
GSK
legal
Zantac
Flag link:
GSK signs shingles vaccine deal with China's Zhifei for around $3 bln
GSK signs shingles vaccine deal with China's Zhifei for around $3 bln
Reuters
GSK
China
Chongqing Zhifei Biological
vaccines
Shingrix
shingles
Flag link:
GSK Seeks Talent to Boost Data Science Capabilities
GSK Seeks Talent to Boost Data Science Capabilities
BioSpace
GSK
artificial intelligence
drug discovery
Flag link:
How a big pharma company stalled a potentially lifesaving vaccine in pursuit of bigger profits
How a big pharma company stalled a potentially lifesaving vaccine in pursuit of bigger profits
Medical Marketing and Media
vaccines
tuberculosis
GSK
ProPublica
Flag link:
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
Fierce Pharma
GSK
HIV
Cabenuva
ViiV Healthcare
Flag link:
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
Fierce Pharma
GSK
FDA
Ojaara
momelotinib
myelofibrosis
Flag link:

Pages